The HSE wants the state to fund the drug Pembro for more women with cervical cancer.
Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.
Under this proposal, all patients with cervical cancer would be able to access the drug. It typically takes about eight months to see whether individual patients respond to Pembrolizumab, which is called Pembro for short.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team